We did not observe changes in ERBB2 amplification status in the majority (7/9 or 78%) of our tumours, consistent with previous reports of loss of HER2-positivity occurring in only 12%–32% of patients undergoing anti-HER2 therapy [68–71]. This evidence concerns the gene ERBB2 and neoplasm.